Skip to main content

Psoriatic arthritis

    On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these as their favorite reports: DAS-28 independently associated survival in RA-ILD. As I keep saying, treating the rheumatoid…
    Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: Secukinumab Efficacy in Enthesitis-Related and Juvenile Psoriatic Arthritis. Abstract 1424 – Dr. Hermine…
    Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions? The NOR-DRUM trials (A and B) are the first randomized trials to assess…
    Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. As a small sample of novel agents demonstrating efficacy in PsA presented at ACR Convergence 2021, we have…
    Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute…
    The third day of ACR 2021 took a big leap in online content.  Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty.  Gender and Secukinumab Rx…
    Highlight reports from Sunday, Day 2 at ACR Convergence included: VITAL Trial: Vitamin D and n-3 Fatty Acid Supplements Protect Against Autoimmune Disease Abstract 0957  – Dr. Karen Costenbader…
    Psoriatic arthritis (PsA) commonly affects peripheral joints. In up to a quarter of PsA patients, the spine may be involved and this is known as psoriatic spondylitis (PsSpA). An important research…
    The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest…
    The first full day of Abstracts and Presentations from ACR Convergence, the 2021 Virtual meeting, was full of highly engaging sessions, quality posters and unique presentations.  To hear more about…